Monthly archive | PharmaTutor

17 July 2026

Interview for Pharma and Science candidates in Manufacturing and Packing at Amneal Pharma

Looking for Supervisor and Operators with Injectable Aseptic Area / Terminal Sterilization Packing experience in Manufacturing.

17 July 2026

Sanofi Require R&D Clinical Trial Support Manager

The CTSM Team leader is responsible to support the clinical study leadership to execute and deliver on our clinical studies.

17 July 2026

Apply Online for Pharmacovigilance Manager at Sun Pharma

Expertise in MS Word and Excel. Experience of working in application like Track Wise and Oracle Argus Safety. Proficiency in oral and written English

17 July 2026

Gepach International Hiring Formulation & Development Manager

Lead formulation development for solid oral dosage forms and other pharmaceutical products. Develop and optimize formulations to achieve desired quality, efficacy and stability.

17 July 2026

Taj Pharma Hiring QC Manager and QC Executive

Execute routine & stability testing of pharmaceutical products. Ensure compliance with WHO-GMP, SOPs & regulatory requirements.

17 July 2026

Production, Quality Control and Quality Assurance Jobs at Aspiro Pharma

QMS & Audit Compliance: Implementation and maintenance of QMS, document control, internal audits, audit preparation, inspection support and CAPA follow-up.

17 July 2026

CDSCO Panel Rejects Dexlansoprazole–Domperidone FDC Proposal

The Subject Expert Committee (SEC) on Gastroenterology and Hepatology has declined to recommend approval of a Fixed Dose Combination (FDC) containing Dexlansoprazole (enteric coated pellets) 60 mg and Domperidone (sustained release pellets) 30 mg capsules proposed by MSN Laboratories Private Limited.

The decision was taken during the 08th/26 SEC meeting held on 9 July 2026 at the CDSCO Headquarters, New Delhi, after the company presented its proposal before the committee.

17 July 2026

FDA Clears First Daily Oral PCSK9 Pill for High Cholesterol

Merck has announced that the US Food and Drug Administration (FDA) has approved LIPFENDRA® (enlicitide) 20 mg, making it the first and only once-daily oral PCSK9 inhibitor for lowering low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). The approval marks the first oral alternative to injectable PCSK9 inhibitors.

17 July 2026

FDA Grants Full Approval to Novartis' Fabhalta for IgA Nephropathy

Novartis has announced that the US Food and Drug Administration (FDA) has granted traditional approval to Fabhalta® (iptacopan) for slowing kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression. The decision follows the drug's accelerated approval in August 2024, which was based on its ability to reduce proteinuria.